PL 14

Drug Profile

PL 14

Alternative Names: PL-14

Latest Information Update: 29 Mar 2006

Price : $50

At a glance

  • Originator Debiopharm
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Endometriosis; Prostate cancer

Most Recent Events

  • 29 Mar 2006 Preregistration for Prostate cancer in Switzerland (unspecified route)
  • 29 Mar 2006 Preregistration for Endometriosis in Switzerland (unspecified route)
  • 26 Aug 2005 Phase-III clinical trials in Prostate cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top